Clinical Trials Browser

Phase 3 × Epstein-Barr Virus Infections × Myeloid × Clear all

NCT05775705 2023-03-20

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Phase 3 Not yet recruiting

LymphoidMyeloid

Lymphoma, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02912702 2016-09-23

L-DEP as an Initial Treatment for EBV-HLH

Phase 3 Unknown

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Phase 3 Unknown

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic